TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
CL2003002353A1
(es)
*
|
2002-11-15 |
2005-02-04 |
Vertex Pharma |
Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
|
JP4847868B2
(ja)
|
2003-05-14 |
2011-12-28 |
ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド |
化合物、及び、アミロイドベータの調節におけるその使用
|
PL1636215T3
(pl)
*
|
2003-05-23 |
2008-09-30 |
Basilea Pharmaceutica Ag |
Furazanobenzymidazole
|
NZ545270A
(en)
*
|
2003-07-30 |
2010-04-30 |
Rigel Pharmaceuticals Inc |
2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
|
AU2005212218A1
(en)
*
|
2004-02-11 |
2005-08-25 |
Janssen Pharmaceutica, N.V. |
Process for the preparation of substituted triazole compounds
|
ES2346323T3
(es)
*
|
2004-02-11 |
2010-10-14 |
Basilea Pharmaceutica Ag |
Bencimidazoles sustituidos y su uso para inducir apoptosis.
|
AU2012205127B2
(en)
*
|
2004-09-17 |
2014-10-30 |
Vertex Pharmaceuticals Incorporated |
Diaminotriazole Compounds Useful as Protein Kinase Inhibitors
|
MX2007003154A
(es)
*
|
2004-09-17 |
2007-05-15 |
Vertex Pharma |
Compuestos de diaminotriazol de utilidad como inhibidores de proteina quinasa.
|
EA200700818A1
(ru)
|
2004-10-08 |
2007-08-31 |
Янссен Фармацевтика, Н.В. |
Производные 1,2,4-триазолиламиноарил(гетероарил)сульфонамидов
|
KR20070073791A
(ko)
|
2004-10-18 |
2007-07-10 |
암젠 인코포레이티드 |
티아디아졸 화합물 및 이의 사용방법
|
TW200630090A
(en)
*
|
2004-10-21 |
2006-09-01 |
Vertex Pharma |
Triazoles useful as inhibitors of protein kinases
|
RU2007123675A
(ru)
*
|
2004-11-24 |
2008-12-27 |
Новартис АГ (CH) |
Комбинации ингибиторов jak
|
HUE029214T2
(en)
|
2005-05-10 |
2017-02-28 |
Incyte Holdings Corp |
Indolamine-2,3-dioxygenase modulators and methods for their use
|
NZ563454A
(en)
|
2005-06-08 |
2011-03-31 |
Rigel Pharmaceuticals Inc |
2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
US8071768B2
(en)
|
2005-06-10 |
2011-12-06 |
Janssen Pharmaceutica, N.V. |
Alkylquinoline and alkylquinazoline kinase modulators
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
US7825244B2
(en)
|
2005-06-10 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
|
US7576053B2
(en)
|
2005-06-13 |
2009-08-18 |
Rigel Pharmaceuticals, Inc. |
Methods and compositions for treating degenerative bone disorders
|
ATE352714T1
(de)
*
|
2005-06-17 |
2007-02-15 |
Magneti Marelli Powertrain Spa |
Brennstoffeinspritzventil
|
DE602006017574D1
(de)
*
|
2005-07-26 |
2010-11-25 |
Vertex Pharma |
Als protein-kinase-inhibitoren nutzbare benzimidazole
|
US7884119B2
(en)
*
|
2005-09-07 |
2011-02-08 |
Rigel Pharmaceuticals, Inc. |
Triazole derivatives useful as Axl inhibitors
|
CA2621261C
(en)
|
2005-09-22 |
2014-05-20 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
KR101443651B1
(ko)
|
2005-10-18 |
2014-09-23 |
얀센 파마슈티카 엔.브이. |
Flt-3 키나제의 억제 방법
|
RS54181B9
(sr)
|
2005-12-13 |
2020-01-31 |
Incyte Holdings Corp |
Heteroaril supstituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
|
EA200801716A1
(ru)
|
2006-01-18 |
2009-04-28 |
Амген Инк. |
Тиазольные соединения и их применение
|
US8962643B2
(en)
*
|
2006-02-24 |
2015-02-24 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
NZ572072A
(en)
|
2006-04-20 |
2011-09-30 |
Janssen Pharmaceutica Nv |
Inhibitors of c-fms kinase
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
AU2007240437B2
(en)
|
2006-04-20 |
2012-12-06 |
Janssen Pharmaceutica N.V. |
Heterocyclic compounds as inhibitors of c-fms kinase
|
BRPI0713187A2
(pt)
*
|
2006-07-20 |
2012-10-16 |
Mehmet Kahraman |
método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
|
WO2008042639A1
(en)
|
2006-10-02 |
2008-04-10 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
US8193197B2
(en)
|
2006-10-19 |
2012-06-05 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
US8513270B2
(en)
|
2006-12-22 |
2013-08-20 |
Incyte Corporation |
Substituted heterocycles as Janus kinase inhibitors
|
WO2008083357A1
(en)
|
2006-12-29 |
2008-07-10 |
Rigel Pharmaceuticals, Inc. |
Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
|
ES2607065T3
(es)
*
|
2006-12-29 |
2017-03-29 |
Rigel Pharmaceuticals, Inc. |
Triazoles N3-heteroaril sustituidos y triazoles N5-heteroaril sustituidos útiles como inhibidores de axl
|
AU2014200825B2
(en)
*
|
2006-12-29 |
2016-05-26 |
Rigel Pharmaceuticals, Inc. |
N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors
|
ES2558477T3
(es)
|
2006-12-29 |
2016-02-04 |
Rigel Pharmaceuticals, Inc. |
Triazoles sustituidos útiles como inhibidores de AXL
|
CN101622246B
(zh)
*
|
2006-12-29 |
2015-09-30 |
里格尔制药公司 |
可用作axl抑制剂的多环杂芳基取代的三唑
|
AU2014200824B2
(en)
*
|
2006-12-29 |
2016-12-15 |
Rigel Pharmaceuticals, Inc. |
Substituted triazoles useful as Axl inhibitors
|
AU2016259396B2
(en)
*
|
2006-12-29 |
2018-11-08 |
Rigel Pharmaceuticals, Inc. |
Substituted triazoles useful as Axl inhibitors
|
WO2008083353A1
(en)
|
2006-12-29 |
2008-07-10 |
Rigel Pharmaceuticals, Inc. |
Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
|
MX2009010127A
(es)
*
|
2007-03-22 |
2009-11-05 |
Vertex Pharma |
Compuestos utiles como inhibidores de janus cinasas.
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
MY154969A
(en)
|
2007-06-13 |
2015-08-28 |
Incyte Corp |
Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
JP2010529990A
(ja)
*
|
2007-06-15 |
2010-09-02 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
タンパク質キナーゼ阻害剤およびそれを使用するための方法
|
AU2008276521B2
(en)
*
|
2007-07-17 |
2011-11-03 |
Amgen Inc. |
Heterocyclic modulators of PKB
|
AU2008276512A1
(en)
|
2007-07-17 |
2009-01-22 |
Amgen Inc. |
Thiadiazole modulators of PKB
|
CA2736564A1
(en)
|
2007-09-10 |
2009-03-19 |
Boston Biomedical, Inc. |
Novel compositions and methods for cancer treatment
|
US20090082470A1
(en)
*
|
2007-09-24 |
2009-03-26 |
Rafal Farjo |
Stat3 inhibiting compositions and methods
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
CA2697974C
(en)
*
|
2007-10-18 |
2015-06-30 |
Janssen Pharmaceutica Nv |
Trisubstituted 1,2,4-triazoles
|
JO2784B1
(en)
*
|
2007-10-18 |
2014-03-15 |
شركة جانسين فارماسوتيكا ان. في |
5,3,1 - Triazole substitute derivative
|
EP2205592B1
(en)
*
|
2007-10-26 |
2013-05-08 |
Rigel Pharmaceuticals, Inc. |
Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
|
JP2011514881A
(ja)
|
2007-11-09 |
2011-05-12 |
ザ ソルク インスティテュート フォー バイオロジカル スタディーズ |
免疫増強剤としてのtam受容体阻害剤の使用および免疫抑制剤としてのtam活性化剤の使用
|
WO2009065132A1
(en)
*
|
2007-11-16 |
2009-05-22 |
Oklahoma Medical Research Foundation |
Predicting and diagnosing patients with autoimmune disease
|
MX2010005300A
(es)
|
2007-11-16 |
2010-06-25 |
Incyte Corp |
4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpir imidin-2-aminas como inhibidores de cinasas janus.
|
AU2009214440B2
(en)
|
2008-02-15 |
2014-09-25 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
|
PT2288610T
(pt)
|
2008-03-11 |
2016-10-17 |
Incyte Holdings Corp |
Derivados de azetidina e de ciclobutano como inibidores de jak
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
AU2009244897B2
(en)
|
2008-04-16 |
2014-11-13 |
Alexion Pharmaceuticals, Inc. |
2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
|
CA2723185A1
(en)
|
2008-04-22 |
2009-10-29 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
CA2722326A1
(en)
|
2008-04-24 |
2009-10-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
MX2010014005A
(es)
*
|
2008-06-20 |
2011-02-15 |
Genentech Inc |
Compuestos de triazolopiridina inhibidores de jak y los metodos.
|
WO2009155565A1
(en)
*
|
2008-06-20 |
2009-12-23 |
Genentech, Inc. |
Triazolopyridine jak inhibitor compounds and methods
|
NZ590268A
(en)
|
2008-07-08 |
2012-11-30 |
Incyte Corp |
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
|
DK2328888T3
(da)
|
2008-07-09 |
2013-02-11 |
Rigel Pharmaceuticals Inc |
Broforbundne, bicykliske heteroarylsubstituerede triazoler, der er anvendelige som axl-inhitorer
|
CA2730231C
(en)
|
2008-07-09 |
2016-10-18 |
Rigel Pharmaceuticals, Inc. |
Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
|
JP5650529B2
(ja)
*
|
2008-07-10 |
2015-01-07 |
一般社団法人ファルマバレープロジェクト支援機構 |
キノリンカルボキサミド誘導体を有効成分とするstat3阻害剤
|
TWI453207B
(zh)
*
|
2008-09-08 |
2014-09-21 |
Signal Pharm Llc |
胺基三唑并吡啶,其組合物及使用其之治療方法
|
MX2011002825A
(es)
*
|
2008-09-18 |
2011-04-05 |
Astellas Pharma Inc |
Compuestos heterociclicos de carboxamida.
|
CL2009001884A1
(es)
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
EP2370580B1
(en)
*
|
2008-12-04 |
2019-09-11 |
CuRNA, Inc. |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
|
JP5657566B2
(ja)
*
|
2008-12-24 |
2015-01-21 |
バイアル ポルテラ アンド シーエイ エス エイBIAL−Portela & Ca, S.A. |
医薬品
|
AU2010204578B2
(en)
*
|
2009-01-16 |
2016-05-12 |
Rigel Pharmaceuticals, Inc. |
AXL inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
|
US8765727B2
(en)
|
2009-01-23 |
2014-07-01 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
CA2755394C
(en)
|
2009-03-13 |
2021-10-19 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
MY156727A
(en)
|
2009-05-22 |
2016-03-15 |
Incyte Corp |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
MX2011012262A
(es)
|
2009-05-22 |
2012-01-25 |
Incyte Corp |
3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak).
|
PL2440555T3
(pl)
*
|
2009-06-09 |
2016-11-30 |
|
Pochodne fluorowanego aminotriazolu
|
WO2011002817A1
(en)
|
2009-06-29 |
2011-01-06 |
Agios Pharmaceuticals, Inc. |
Therapeutic compounds and compositions
|
RS53494B9
(sr)
|
2009-06-29 |
2020-11-30 |
Incyte Holdings Corp |
Pirimidinoni kao inhibitori pi3k
|
AU2010281404A1
(en)
*
|
2009-07-28 |
2012-02-09 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
US9249145B2
(en)
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
CN105541847B
(zh)
|
2009-10-09 |
2019-08-16 |
因西特控股公司 |
3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
|
ES2594402T3
(es)
|
2009-10-21 |
2016-12-20 |
Agios Pharmaceuticals, Inc. |
Métodos y composiciones para trastornos relacionados con la proliferación celular
|
TW201130842A
(en)
|
2009-12-18 |
2011-09-16 |
Incyte Corp |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
US8759359B2
(en)
|
2009-12-18 |
2014-06-24 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as PI3K inhibitors
|
WO2011083124A1
(en)
|
2010-01-05 |
2011-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Flt3 receptor antagonists for the treatment or the prevention of pain disorders
|
WO2011086085A1
(en)
|
2010-01-12 |
2011-07-21 |
Ab Science |
Thiazole and oxazole kinase inhibitors
|
CA2787365A1
(en)
*
|
2010-01-25 |
2011-07-28 |
Chdi Foundation, Inc. |
Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
|
CA2790070C
(en)
|
2010-02-18 |
2018-03-06 |
Incyte Corporation |
Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
|
KR102283091B1
(ko)
|
2010-03-10 |
2021-07-30 |
인사이트 홀딩스 코포레이션 |
Jak1 저해제로서의 피페리딘4일 아제티딘 유도체
|
NZ712826A
(en)
*
|
2010-03-19 |
2017-03-31 |
Boston Biomedical Inc |
Novel compounds and compositions for targeting cancer stem cells
|
FI2547205T3
(fi)
*
|
2010-03-19 |
2024-05-27 |
1Globe Biomedical Co Ltd |
Uusia menetelmiä syövän kantasolujen kohdentamiseksi
|
MX345552B
(es)
*
|
2010-03-24 |
2017-02-02 |
Amitech Therapeutic Solutions Inc |
Compuestos heterocíclicos útiles para inhibición de cinasa.
|
WO2011130342A1
(en)
|
2010-04-14 |
2011-10-20 |
Incyte Corporation |
FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
|
TWI499421B
(zh)
|
2010-05-21 |
2015-09-11 |
Incyte Corp |
Jak抑制劑的局部製劑
|
WO2011163195A1
(en)
|
2010-06-21 |
2011-12-29 |
Incyte Corporation |
Fused pyrrole derivatives as pi3k inhibitors
|
JP2012102090A
(ja)
*
|
2010-10-15 |
2012-05-31 |
Sumitomo Chemical Co Ltd |
ピリミジン化合物およびその有害生物防除用途
|
US9102625B2
(en)
|
2010-11-01 |
2015-08-11 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as JAK kinase modulators
|
CA2818545C
(en)
|
2010-11-19 |
2019-04-16 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
BR112013012502A2
(pt)
|
2010-11-19 |
2019-03-06 |
Incyte Corporation |
pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
|
WO2012087881A1
(en)
|
2010-12-20 |
2012-06-28 |
Incyte Corporation |
N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
|
CN103732226B
(zh)
|
2011-02-18 |
2016-01-06 |
诺瓦提斯药物公司 |
mTOR/JAK抑制剂组合疗法
|
CA2827875A1
(en)
*
|
2011-03-01 |
2012-10-18 |
Npharmakon, Llc |
Use of n-(4-methoxyphenyl)-1-phenyl-1h-pyrazol-3-amine and related compounds
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
US9126948B2
(en)
|
2011-03-25 |
2015-09-08 |
Incyte Holdings Corporation |
Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
|
ES2675903T3
(es)
|
2011-05-03 |
2018-07-13 |
Agios Pharmaceuticals, Inc. |
Activadores de piruvato quinasa para uso en terapia
|
CN102827073A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
CN102827170A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
MY165963A
(en)
|
2011-06-20 |
2018-05-18 |
Incyte Holdings Corp |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
JP2014521725A
(ja)
|
2011-08-10 |
2014-08-28 |
ノバルティス・ファルマ・アクチェンゲゼルシャフト |
JAKPI3K/mTOR併用療法
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
ES2629194T3
(es)
|
2011-08-30 |
2017-08-07 |
Chdi Foundation, Inc. |
Inhibidores de kinurenina-3-monoxigenasa, composiciones farmacéuticas y métodos de utilización del mismo
|
CN103827095A
(zh)
|
2011-08-30 |
2014-05-28 |
Chdi基金会股份有限公司 |
犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法
|
IL299533A
(en)
|
2011-09-02 |
2023-02-01 |
Incyte Holdings Corp |
Heterocycloamines as P13K inhibitors
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
WO2013049591A2
(en)
*
|
2011-09-29 |
2013-04-04 |
Verseon Corporation |
Dual inhibitor compounds and methods of use thereof
|
WO2013078466A1
(en)
|
2011-11-23 |
2013-05-30 |
Portola Pharmaceuticals, Inc. |
Pyrazine kinase inhibitors
|
CN107417667B
(zh)
|
2012-01-06 |
2020-04-10 |
安吉奥斯医药品有限公司 |
治疗活性化合物及其使用方法
|
US9474779B2
(en)
|
2012-01-19 |
2016-10-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their methods of use
|
EP2819517A2
(en)
*
|
2012-02-14 |
2015-01-07 |
Grl |
Small molecule having antiviral properties
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
HUE034430T2
(en)
|
2012-05-08 |
2018-02-28 |
Bayer Pharma AG |
Process for the preparation of triazole compounds
|
WO2013173720A1
(en)
|
2012-05-18 |
2013-11-21 |
Incyte Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
CA2876689C
(en)
|
2012-06-13 |
2022-04-26 |
Incyte Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
US20140010783A1
(en)
*
|
2012-07-06 |
2014-01-09 |
Hoffmann-La Roche Inc. |
Antiviral compounds
|
WO2014011540A1
(en)
*
|
2012-07-09 |
2014-01-16 |
Emory University |
Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
|
WO2014025675A1
(en)
|
2012-08-07 |
2014-02-13 |
Janssen Pharmaceutica Nv |
Process for the preparation of heterocyclic ester derivatives
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
JP6407504B2
(ja)
|
2012-09-21 |
2018-10-17 |
アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. |
恒常的に活性であるリン酸化型flt3キナーゼの阻害方法
|
EP2903970A4
(en)
|
2012-10-08 |
2016-11-30 |
Portola Pharm Inc |
SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
|
CA2888360A1
(en)
|
2012-10-15 |
2014-04-24 |
Agios Pharmaceuticals, Inc. |
Therapeutic compounds and compositions
|
BR112015009942A2
(pt)
|
2012-11-01 |
2017-07-11 |
Incyte Corp |
derivados de tiofeno fundidos tricíclicos como inibidores de jak
|
KR20210037012A
(ko)
|
2012-11-15 |
2021-04-05 |
인사이트 홀딩스 코포레이션 |
룩솔리티니브의 서방성 제형
|
BR112015016282A2
(pt)
|
2013-01-07 |
2017-07-11 |
Arog Pharmaceuticals Inc |
crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
|
TW202214254A
(zh)
|
2013-03-01 |
2022-04-16 |
美商英塞特控股公司 |
吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
|
WO2014135471A1
(en)
*
|
2013-03-05 |
2014-09-12 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
JP6122514B2
(ja)
*
|
2013-03-05 |
2017-04-26 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
抗ウイルス化合物
|
RU2015137966A
(ru)
|
2013-03-06 |
2017-04-06 |
Ф. Хоффманн-Ля Рош Аг |
Противовирусные соединения
|
NZ711976A
(en)
|
2013-03-06 |
2019-01-25 |
Incyte Holdings Corp |
Processes and intermediates for making a jak inhibitor
|
RU2015147696A
(ru)
|
2013-04-09 |
2017-05-12 |
Бостон Байомедикал, Инк. |
Способы лечения злокачественной опухоли
|
RS56924B9
(sr)
|
2013-04-19 |
2019-09-30 |
Incyte Holdings Corp |
Biciklični heterocikli kao fgfr inhibitori
|
SG11201509180WA
(en)
|
2013-05-17 |
2015-12-30 |
Incyte Corp |
Bipyrazole derivatives as jak inhibitors
|
US9579324B2
(en)
|
2013-07-11 |
2017-02-28 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
BR112016000489A8
(pt)
|
2013-07-11 |
2020-01-07 |
Agios Pharmaceuticals Inc |
composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
|
WO2015003355A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
WO2015003360A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
JP6529492B2
(ja)
*
|
2013-07-11 |
2019-06-12 |
アジオス ファーマシューティカルズ, インコーポレイテッド |
癌の処置のためのidh2突然変異体阻害剤としての2,4−または4,6−ジアミノピリミジン化合物
|
US20150031627A1
(en)
|
2013-07-25 |
2015-01-29 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
SG10201801069QA
(en)
|
2013-08-07 |
2018-03-28 |
Incyte Corp |
Sustained release dosage forms for a jak1 inhibitor
|
CN105555313A
(zh)
|
2013-08-20 |
2016-05-04 |
因赛特公司 |
在c-反应蛋白水平较高的实体肿瘤患者中的存活益处
|
US10463658B2
(en)
|
2013-10-25 |
2019-11-05 |
Videra Pharmaceuticals, Llc |
Method of inhibiting FLT3 kinase
|
EA201691745A1
(ru)
|
2014-02-28 |
2016-12-30 |
Инсайт Корпорейшн |
Ингибиторы jak1 для лечения миелодиспластических синдромов
|
KR20240010105A
(ko)
|
2014-03-14 |
2024-01-23 |
아지오스 파마슈티컬스 아이엔씨. |
치료적으로 활성인 화합물의 약제학적 조성물
|
EA201692011A1
(ru)
|
2014-04-08 |
2017-01-30 |
Инсайт Корпорейшн |
Лечение b-клеточных злокачественных новообразований с применением комбинации ингибиторов jak и pi3k
|
CR20160553A
(es)
|
2014-04-30 |
2017-04-25 |
Incyte Corp |
Procesos para preparar un inhibidor de jak1 y nuevas formas de este
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
WO2015191677A1
(en)
|
2014-06-11 |
2015-12-17 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
|
UA120856C2
(uk)
|
2014-07-17 |
2020-02-25 |
Кхді Фаундейшн, Інк. |
Способи та композиції для лікування розладів, пов'язаних з віл
|
WO2016016370A1
(en)
|
2014-07-31 |
2016-02-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Flt3 receptor antagonists
|
WO2016130501A1
(en)
|
2015-02-09 |
2016-08-18 |
Incyte Corporation |
Aza-heteroaryl compounds as pi3k-gamma inhibitors
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
MX2017010673A
(es)
|
2015-02-20 |
2018-03-21 |
Incyte Corp |
Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
|
MA55193B1
(fr)
|
2015-02-27 |
2022-10-31 |
Incyte Holdings Corp |
Procédés de préparation d'un inhibiteur de pi3k
|
WO2016183062A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
MX2017016041A
(es)
|
2015-06-11 |
2018-04-24 |
Agios Pharmaceuticals Inc |
Metodos para usar activadores de piruvato cinasa.
|
BR112018007656A2
(pt)
|
2015-10-15 |
2018-11-06 |
Agios Pharmaceuticals Inc |
terapia de combinação para tratamento de doenças malignas
|
MX2018004587A
(es)
|
2015-10-15 |
2018-08-14 |
Agios Pharmaceuticals Inc |
Terapia de combinacion para tratar tumores malignos.
|
TWI824309B
(zh)
|
2015-11-06 |
2023-12-01 |
美商英塞特公司 |
作為PI3K-γ抑制劑之雜環化合物
|
AR107293A1
(es)
|
2016-01-05 |
2018-04-18 |
Incyte Corp |
COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g
|
EP3241830A1
(de)
|
2016-05-04 |
2017-11-08 |
Bayer CropScience Aktiengesellschaft |
Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
|
EP3254698A1
(en)
|
2016-06-08 |
2017-12-13 |
Universite De Montpellier |
Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
|
US10138248B2
(en)
|
2016-06-24 |
2018-11-27 |
Incyte Corporation |
Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
|
EP3484854B1
(en)
*
|
2016-07-18 |
2021-01-20 |
National Institute Of Biological Sciences, Beijing |
Apoptosis inhibitors
|
MX2019005008A
(es)
|
2016-11-02 |
2019-09-10 |
Arog Pharmaceuticals Inc |
Crenolanib para tratar mutaciones asociadas a trastornos proliferativos de flt3 mutado.
|
WO2018102427A1
(en)
|
2016-11-29 |
2018-06-07 |
Boston Biomedical, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
RU2629360C1
(ru)
*
|
2016-12-08 |
2017-08-29 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский технологический университет" |
НОВЫЕ 1-β-D-РИБОФУРАНОЗИЛ-3-(5-ЗАМЕЩЕННЫЕ-1,2,4-ОКСАДИАЗОЛ-3-ИЛ)-1,2,4-ТРИАЗОЛЫ, ОБЛАДАЮЩИЕ ПРОТИВОВИРУСНЫМИ СВОЙСТВАМИ, И СПОСОБ ИХ ПОЛУЧЕНИЯ
|
WO2018211018A1
(en)
|
2017-05-17 |
2018-11-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Flt3 inhibitors for improving pain treatments by opioids
|
WO2018213424A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
WO2019057649A1
(en)
|
2017-09-19 |
2019-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
|
MD3697789T2
(ro)
|
2017-10-18 |
2022-02-28 |
Incyte Corp |
Derivați imidazol condensați substituiți cu grupări hidroxi terțiare ca inhibitori PI3K-GAMA
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
US11306079B2
(en)
|
2017-12-21 |
2022-04-19 |
Incyte Corporation |
3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors
|
GB201801226D0
(en)
*
|
2018-01-25 |
2018-03-14 |
Redx Pharma Plc |
Modulators of Rho-associated protein kinase
|
EP3746429B1
(en)
|
2018-01-30 |
2022-03-09 |
Incyte Corporation |
Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
PE20212186A1
(es)
|
2018-02-16 |
2021-11-11 |
Incyte Corp |
Inhibidores de la via de jak1 para el tratamiento de trastornos relacionados con citoquinas
|
CN117903140A
(zh)
|
2018-02-27 |
2024-04-19 |
因赛特公司 |
作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
|
JP7268049B2
(ja)
|
2018-03-08 |
2023-05-02 |
インサイト・コーポレイション |
PI3K-γ阻害剤としてのアミノピラジンジオール化合物
|
EA202092343A1
(ru)
|
2018-03-30 |
2021-01-20 |
Инсайт Корпорейшн |
Лечение гнойного гидраденита с использованием ингибиторов jak
|
EP3775284A1
(en)
|
2018-03-30 |
2021-02-17 |
Incyte Corporation |
Biomarkers for inflammatory skin disease
|
US11220510B2
(en)
|
2018-04-09 |
2022-01-11 |
Incyte Corporation |
Pyrrole tricyclic compounds as A2A / A2B inhibitors
|
SG11202010068VA
(en)
|
2018-04-25 |
2020-11-27 |
Bayer Ag |
Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
|
EP3788047A2
(en)
|
2018-05-04 |
2021-03-10 |
Incyte Corporation |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
SG11202010882XA
(en)
|
2018-05-04 |
2020-11-27 |
Incyte Corp |
Salts of an fgfr inhibitor
|
MA52940A
(fr)
|
2018-05-18 |
2021-04-28 |
Incyte Corp |
Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
|
WO2019227007A1
(en)
|
2018-05-25 |
2019-11-28 |
Incyte Corporation |
Tricyclic heterocyclic compounds as sting activators
|
AU2019280590B2
(en)
*
|
2018-06-04 |
2022-11-17 |
Ac Immune Sa |
Tetrahydrobenzofuro[2,3-c]pyridine and beta-carboline compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates
|
US10980788B2
(en)
|
2018-06-08 |
2021-04-20 |
Agios Pharmaceuticals, Inc. |
Therapy for treating malignancies
|
WO2020010003A1
(en)
|
2018-07-02 |
2020-01-09 |
Incyte Corporation |
AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
|
SG11202013216RA
(en)
|
2018-07-05 |
2021-01-28 |
Incyte Corp |
Fused pyrazine derivatives as a2a / a2b inhibitors
|
WO2020028566A1
(en)
|
2018-07-31 |
2020-02-06 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
US11008344B2
(en)
|
2018-07-31 |
2021-05-18 |
Incyte Corporation |
Tricyclic heteroaryl compounds as STING activators
|
WO2020036133A1
(ja)
*
|
2018-08-17 |
2020-02-20 |
クミアイ化学工業株式会社 |
3-(1h-1,2,4-トリアゾール-1-イル)安息香酸アミド誘導体及び有害生物防除剤
|
JP2021535182A
(ja)
|
2018-09-05 |
2021-12-16 |
インサイト・コーポレイションIncyte Corporation |
ホスホイノシチド3−キナーゼ(pi3k)阻害剤の結晶形態
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
WO2020102198A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
WO2020102150A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
WO2020102216A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Substituted heterocyclic derivatives as pi3k inhibitors
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
WO2020146237A1
(en)
|
2019-01-07 |
2020-07-16 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
WO2020168178A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Cyclin-dependent kinase 2 biomarkers and uses thereof
|
US11472791B2
(en)
|
2019-03-05 |
2022-10-18 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
EP3982971A4
(en)
|
2019-06-10 |
2023-08-16 |
Incyte Corporation |
TOPICAL TREATMENT OF VITILIGO BY A JAK INHIBITOR
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
UY38794A
(es)
|
2019-07-23 |
2021-02-26 |
Bayer Ag |
Novedosos compuestos de heteroaril-triazol como plaguicidas
|
CA3148209A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Aktiengesellschaft |
Novel heteroaryl-triazole compounds as pesticides
|
MX2022001133A
(es)
|
2019-08-01 |
2022-04-25 |
Incyte Corp |
Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).
|
AR119765A1
(es)
|
2019-08-14 |
2022-01-12 |
Incyte Corp |
Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
|
CN114585625A
(zh)
|
2019-08-26 |
2022-06-03 |
因赛特公司 |
作为a2a/a2b抑制剂的三唑并嘧啶
|
WO2021072232A1
(en)
|
2019-10-11 |
2021-04-15 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
MX2022004513A
(es)
|
2019-10-14 |
2022-07-19 |
Incyte Corp |
Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
|
US11992490B2
(en)
|
2019-10-16 |
2024-05-28 |
Incyte Corporation |
Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
|
JP2023506118A
(ja)
|
2019-10-16 |
2023-02-15 |
インサイト・コーポレイション |
皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
CR20220285A
(es)
|
2019-12-04 |
2022-10-27 |
Incyte Corp |
Derivados de un inhibidor de fgfr
|
US11897891B2
(en)
|
2019-12-04 |
2024-02-13 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
IL296065A
(en)
|
2020-03-06 |
2022-10-01 |
Incyte Corp |
Combined treatment including axl/mer and pd-1/pd-l1 inhibitors
|
BR112022020841A2
(pt)
|
2020-04-16 |
2023-05-02 |
Incyte Corp |
Inibidores de kras tricíclicos fundidos
|
GB202006382D0
(en)
|
2020-04-30 |
2020-06-17 |
Spermatech As |
Use
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
AR122505A1
(es)
|
2020-06-02 |
2022-09-14 |
Incyte Corp |
Procesos para preparar un inhibidor de jak1
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
WO2022019998A1
(en)
|
2020-07-20 |
2022-01-27 |
Arog Pharmaceuticals, Inc. |
Crystal forms of crenolanib and methods of use thereof
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
CN116261447A
(zh)
|
2020-09-16 |
2023-06-13 |
因赛特公司 |
局部治疗白癜风
|
US11767320B2
(en)
|
2020-10-02 |
2023-09-26 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of KRAS
|
US11969420B2
(en)
|
2020-10-30 |
2024-04-30 |
Arog Pharmaceuticals, Inc. |
Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
|
IL303238A
(en)
|
2020-12-08 |
2023-07-01 |
Incyte Corp |
Jak1 pathway inhibitors for the treatment of vitiligo
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含fgfr抑制劑及nectin-4靶向劑之組合療法
|
WO2022261160A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
TW202313610A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為fgfr抑制劑之三環雜環
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
EP4367117A1
(en)
|
2021-07-07 |
2024-05-15 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
WO2023287896A1
(en)
|
2021-07-14 |
2023-01-19 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
US20230174555A1
(en)
|
2021-08-31 |
2023-06-08 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
US20230151005A1
(en)
|
2021-09-21 |
2023-05-18 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
US20230143938A1
(en)
|
2021-10-01 |
2023-05-11 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
WO2023064458A1
(en)
*
|
2021-10-13 |
2023-04-20 |
Yale University |
Selective jak2 inhibitors and methods of use
|
WO2023064857A1
(en)
|
2021-10-14 |
2023-04-20 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|
WO2023091746A1
(en)
|
2021-11-22 |
2023-05-25 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a kras inhibitor
|
TW202329937A
(zh)
|
2021-12-03 |
2023-08-01 |
美商英塞特公司 |
雙環胺ck12抑制劑
|
WO2023107705A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
TW202340215A
(zh)
|
2021-12-22 |
2023-10-16 |
美商英塞特公司 |
Fgfr抑制劑之鹽及固體形式以及其製備方法
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
TW202341982A
(zh)
|
2021-12-24 |
2023-11-01 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Cdk2抑制劑及其用途
|
US20230279004A1
(en)
|
2022-03-07 |
2023-09-07 |
Incyte Corporation |
Solid forms, salts, and processes of preparation of a cdk2 inhibitor
|
WO2023245053A1
(en)
|
2022-06-14 |
2023-12-21 |
Incyte Corporation |
Solid forms of a jak inhibitor and process of preparing the same
|
WO2023250430A1
(en)
|
2022-06-22 |
2023-12-28 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
WO2024015731A1
(en)
|
2022-07-11 |
2024-01-18 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
US20240058343A1
(en)
|
2022-08-05 |
2024-02-22 |
Incyte Corporation |
Treatment of urticaria using jak inhibitors
|
WO2024051667A1
(zh)
*
|
2022-09-05 |
2024-03-14 |
南京正大天晴制药有限公司 |
具有axl抑制活性的取代三唑化合物
|